Snowden Pencer Seeks Laparoscopy Partner Following Genzyme Spin-Off
This article was originally published in The Gray Sheet
Executive Summary
Snowden Pencer, Inc. is seeking a marketing and distribution partner for its line of laparoscopic instruments in the wake of a management-led buyout from Genzyme Biosurgery
You may also be interested in...
Cardiothoracic Sale Contemplated As Genzyme Ends Tracking Stock Strategy
Genzyme Biosurgery plans to divest the bulk of its cardiothoracic devices business by year-end to focus on its orthopedics and biosurgical specialties units
Cardiothoracic Sale Contemplated As Genzyme Ends Tracking Stock Strategy
Genzyme Biosurgery plans to divest the bulk of its cardiothoracic devices business by year-end to focus on its orthopedics and biosurgical specialties units
Genzyme Biosurgery Restructuring Emphasizes R&D Over Hardware
Genzyme Biosurgery intends to redirect a portion of its roughly $45 mil. annual R&D budget toward early stage studies of cell therapy for cardiac indications and potential uses of gene therapy during cardiac surgery.